Welcome on board!
Pharnext is an advanced clinical-stage biopharmaceutical company committed to developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying.
Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships. Both of Pharnext’s lead assets originated from the Pleotherapy R&D approach.
Date
Total number of shares composing the share capital
August 31, 2023
3 909 336 626 (1)
(1) This table will be subject to a monthly update of (i) the number of shares issued from the convertible bond program announced on June 7, 2021, with Global Tech Opportunities 13, and (ii) the OBSA program announced on October 3, 2022 with Equitis Gestion (a management trust set up by Néovacs), detailed in follow-up tables available HERE
Stock Market
Euronext Growth Paris
Mnemo
ALPHA
Bloomberg
ALPHA/FR – Reuters: ALPHA.PA
ISIN Code
FR001400JXB0
Closing date
31 December
First day of trading
18 July 2016
Number of shares
See table above
Indices
EnterNext© PEA-PME 150,
Euronext Growth All-Share, Next Biotech, PEA
Liquidity contract
Kepler Cheuvreux
Eligible to PEA-PME (French fiscal advantage)
Share price
The analysts listed on the right follow PHARNEXT. Any opinions, estimates or forecasts made by these analysts regarding PHARNEXT are individual and do not represent opinions, forecasts or predictions of PHARNEXT's management. PHARNEXT does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.
Initiation of coverage report*
R&D Day 2020 Event report*
Report on PREMIER trial initiation*
Report on the Open-Label Phase III Extension Study of PXT3003*
R&D Day 2021 Event report*
Report on PREMIER trial completed recruitment*
Report on €12m new loan*
Corporate update note (June, 2022)*
Neovacs €2.5m loan*
First patient enrolled in PREMIER extension study*
Neovacs €20.7m funding*
Funding headroom to support PXT3003 progress*
Revised legal structure to offer operational stability*
Improving FY23 financial footing*
Potential licensing deals could add confidence*
* These hyperlinks to a third party website are provided for information only and do not constitute an endorsement of any content provided therein.
Ajustement de la valeur nominale (only in French)
Pharnext updates on the development program in China for PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A)
Edison Investment Research maintains its valuation following the Company's latest announcements
Levée de fonds de 1,3 million d’euros (only in French)
Pharnext enters the final stretch for the signature of a licensing agreement for its drug candidate in Charcot-Marie-Tooth disease type 1A (PXT3003), enabling it to capitalize on its assets and put an end to the OCEANE-BSA financing line
Corporate presentation
Pharnext corporate presentation
Presentation of the R&D Day 2021
Video recording of the R&D Day 2021
Presentation of the PLEO-CMT-FU extension study update
Recording of the webcast presentation of the PLEO-CMT-FU extension study update
General Meeting
General Meeting
General Meeting
General Meeting
General Meeting
General Meeting
General meeting
General meeting
General meeting
General meeting
General meeting
Letter to shareholders
Letter to Shareholders
Letter to Shareholders
Letter to Shareholders
Letter to Shareholders
Letter to Shareholders
Letter to Shareholders
Letter to Shareholders
Regulated Information
Rapport de gestion 2022 (French only)
Rapport des CAC sur les comptes annuels 2022 (French only)
Rapport des CAC sur les comptes IFRS 2022 (French only)
Rapport ad hoc des CAC (French only)
Attestation des CAC sur les rémunérations 2022 (French only)